We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

1qbs

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1qbs.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1qbs.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1qbs| PDB=1qbs | SCENE= }}
{{STRUCTURE_1qbs| PDB=1qbs | SCENE= }}
-
'''HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY'''
+
===HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY===
-
==Overview==
+
<!--
-
High-resolution X-ray structures of the complexes of HIV-1 protease (HIV-1PR) with peptidomimetic inhibitors reveal the presence of a structural water molecule which is hydrogen bonded to both the mobile flaps of the enzyme and the two carbonyls flanking the transition-state mimic of the inhibitors. Using the structure-activity relationships of C2-symmetric diol inhibitors, computed-aided drug design tools, and first principles, we designed and synthesized a novel class of cyclic ureas that incorporates this structural water and preorganizes the side chain residues into optimum binding conformations. Conformational analysis suggested a preference for pseudodiaxial benzylic and pseudodiequatorial hydroxyl substituents and an enantiomeric preference for the RSSR stereochemistry. The X-ray and solution NMR structure of the complex of HIV-1PR and one such cyclic urea, DMP323, confirmed the displacement of the structural water. Additionally, the bound and "unbound" (small-molecule X-ray) ligands have similar conformations. The high degree of preorganization, the complementarity, and the entropic gain of water displacement are proposed to explain the high affinity of these small molecules for the enzyme. The small size probably contributes to the observed good oral bioavailability in animals. Extensive structure-based optimization of the side chains that fill the S2 and S2' pockets of the enzyme resulted in DMP323, which was studied in phase I clinical trials but found to suffer from variable pharmacokinetics in man. This report details the synthesis, conformational analysis, structure-activity relationships, and molecular recognition of this series of C2-symmetry HIV-1PR inhibitors. An initial series of cyclic ureas containing nonsymmetric P2/P2' is also discussed.
+
The line below this paragraph, {{ABSTRACT_PUBMED_8784449}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 8784449 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_8784449}}
==About this Structure==
==About this Structure==
Line 26: Line 30:
[[Category: Chang, C H.]]
[[Category: Chang, C H.]]
[[Category: Aspartyl protease]]
[[Category: Aspartyl protease]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 06:06:34 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 09:29:12 2008''

Revision as of 06:29, 28 July 2008

Image:1qbs.png

Template:STRUCTURE 1qbs

HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY

Template:ABSTRACT PUBMED 8784449

About this Structure

1QBS is a Single protein structure of sequence from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.

Reference

Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas., Lam PY, Ru Y, Jadhav PK, Aldrich PE, DeLucca GV, Eyermann CJ, Chang CH, Emmett G, Holler ER, Daneker WF, Li L, Confalone PN, McHugh RJ, Han Q, Li R, Markwalder JA, Seitz SP, Sharpe TR, Bacheler LT, Rayner MM, Klabe RM, Shum L, Winslow DL, Kornhauser DM, Hodge CN, et al., J Med Chem. 1996 Aug 30;39(18):3514-25. PMID:8784449

Page seeded by OCA on Mon Jul 28 09:29:12 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1qbs"
Personal tools